Literature DB >> 7591598

Results of salvage retroperitoneal lymphadenectomy (RLA) in the treatment of patients with nonseminomatous germ cell tumours remaining marker positive after inductive chemotherapy.

L Kisbenedek1, I Bodrogi, P Szeldeli, M Baki, P Tenke, J Horti.   

Abstract

The authors describe the evidence and results obtained in 21 out of 100 patients who underwent salvage retroperitoneal lymphadenectomy for advanced testicular cancer (UICC stage II/B bulky and stage III) in the period 1982-1993, and in whom inductive chemotherapy was not followed by marker conversion. It is stated that if AFP positivity is low (titres below 100 ng/ml) salvage retroperitoneal lymphadenectomy (RLA) is of high therapeutic value, whereas in all cases with HCG positivity or AFP titres higher than 500 ng/ml tumorous death ensued without exception. In our cases viable tumour residues occurred in 81%. Salvage resection was feasible in 76%, but every incomplete resection (19%) was followed by death due to tumour. In all but one of the cases marker positivity, an indicator of therapy-resistant viable tumour residues, persisted after having used more than four PVB combinations or changes in the chemotherapeutic regimen.

Entities:  

Mesh:

Substances:

Year:  1995        PMID: 7591598     DOI: 10.1007/BF02564770

Source DB:  PubMed          Journal:  Int Urol Nephrol        ISSN: 0301-1623            Impact factor:   2.370


  10 in total

1.  The role of ifosfamide plus cisplatin-based chemotherapy as salvage therapy for patients with refractory germ cell tumors.

Authors:  R J Motzer; K Cooper; N L Geller; D F Bajorin; E Dmitrovsky; H Herr; M Morse; W Fair; P Sogani; P Russo
Journal:  Cancer       Date:  1990-12-15       Impact factor: 6.860

2.  Para-aortic lymphadenectomy after chemotherapy for metastatic non-seminomatous germ cell tumours: prognostic value and therapeutic benefit.

Authors:  W F Hendry; R P A'Hern; J W Hetherington; M J Peckham; D P Dearnaley; A Horwich
Journal:  Br J Urol       Date:  1993-02

3.  Elevated serum tumor markers in patients with testicular cancer after induction chemotherapy due to a reservoir of markers in cystic differentiated mature teratoma.

Authors:  A van der Gaast; J W Hoekstra; J J Croles; T A Splinter
Journal:  J Urol       Date:  1991-04       Impact factor: 7.450

4.  Surgical resection of solitary metastases after chemotherapy in patients with nonseminomatous germ cell tumors and elevated serum tumor markers.

Authors:  D P Wood; H W Herr; R J Motzer; V Reuter; P C Sogani; M J Morse; G J Bosl
Journal:  Cancer       Date:  1992-11-01       Impact factor: 6.860

5.  Surgical resection in patients with nonseminomatous germ cell tumor who fail to normalize serum tumor markers after chemotherapy.

Authors:  J A Eastham; T G Wilson; C Russell; T E Ahlering; D G Skinner
Journal:  Urology       Date:  1994-01       Impact factor: 2.649

6.  [Limitations of tumor marker surveillance after chemotherapy in advanced non-seminomatous testicular tumors].

Authors:  H Behrendt; R H Ringert; R Pfeiffer; W Homann; R Hartung
Journal:  Urol Int       Date:  1983       Impact factor: 2.089

7.  Surgical salvage of chemorefractory germ cell tumors.

Authors:  B R Murphy; E S Breeden; J P Donohue; J Messemer; W Walsh; B J Roth; L H Einhorn
Journal:  J Clin Oncol       Date:  1993-02       Impact factor: 44.544

8.  Tumor markers in testis cancer.

Authors:  E A Klein
Journal:  Urol Clin North Am       Date:  1993-02       Impact factor: 2.241

9.  [The "false positive" tumor marker in malignant testicular tumor].

Authors:  R Bussar-Maatz; L Weissbach; N Dahlmann; K Mann
Journal:  Urologe A       Date:  1993-05       Impact factor: 0.639

10.  Sexual function after surgery and combination chemotherapy in men with disseminated nonseminomatous testicular cancer.

Authors:  J M Nijman; H Schraffordt Koops; J Oldhoff; J Kremer; D T Sleijfer
Journal:  J Surg Oncol       Date:  1988-07       Impact factor: 3.454

  10 in total
  1 in total

Review 1.  A review of second-line chemotherapy and prognostic models for disseminated germ cell tumors.

Authors:  Martin H Voss; Darren R Feldman; George J Bosl; Robert J Motzer
Journal:  Hematol Oncol Clin North Am       Date:  2011-04-22       Impact factor: 3.722

  1 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.